STRO Sutro Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: STRO

Price (delayed)

$15.73

Market cap

$260.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$17.36

Enterprise value

$216.41M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29
Highlights
The company's debt fell by 45% YoY and by 21% QoQ
The quick ratio has grown by 12% YoY and by 6% from the previous quarter
STRO's EPS is up by 31% YoY but it is down by 6% from the previous quarter
STRO's net income is down by 18% from the previous quarter but it is up by 13% YoY
The gross profit has plunged by 56% YoY and by 54% from the previous quarter
Sutro Biopharma's revenue has shrunk by 56% YoY and by 54% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sutrobio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of STRO

STRO stock price

How has the Sutro Biopharma stock price performed over time
Intraday
-2.48%
1 week
0.83%
1 month
-25.24%
1 year
89.98%
YTD
35.96%
QTD
-52.62%

Financial performance

How have Sutro Biopharma's revenue and profit performed over time
Revenue
$45.7M
Gross profit
$45.7M
Operating income
-$146.05M
Net income
-$180.64M
Gross margin
100%
Net margin
-395.2%
STRO's operating margin has shrunk by 166% QoQ and by 63% YoY
The company's net margin has shrunk by 156% QoQ and by 98% YoY
The gross profit has plunged by 56% YoY and by 54% from the previous quarter
Sutro Biopharma's revenue has shrunk by 56% YoY and by 54% QoQ

Price vs fundamentals

How does STRO's price correlate with its fundamentals

Growth

What is Sutro Biopharma's growth rate over time

Valuation

What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
5.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.74
STRO's EPS is up by 31% YoY but it is down by 6% from the previous quarter
The equity has dropped by 54% since the previous quarter
Sutro Biopharma's revenue has shrunk by 56% YoY and by 54% QoQ
The stock's price to sales (P/S) is 39% more than its last 4 quarters average of 4.2 and 33% more than its 5-year quarterly average of 4.4

Efficiency

How efficient is Sutro Biopharma business performance
STRO's ROS has plunged by 157% from the previous quarter and by 126% YoY
STRO's return on assets has dropped by 50% year-on-year and by 27% since the previous quarter
STRO's return on invested capital is down by 41% year-on-year and by 33% since the previous quarter

Dividends

What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for STRO.

Financial health

How did Sutro Biopharma financials performed over time
STRO's total assets is 35% smaller than its total liabilities
STRO's total assets is down by 26% year-on-year and by 20% since the previous quarter
The quick ratio has grown by 12% YoY and by 6% from the previous quarter
The company's debt is 110% higher than its equity
Sutro Biopharma's debt to equity has soared by 84% YoY and by 50% from the previous quarter
The equity has dropped by 54% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.